TARDIS: Triple Antiplatelet Therapy No Benefit in Stroke, TIA TARDIS: Triple Antiplatelet Therapy No Benefit in Stroke, TIA

Triple antiplatelet therapy was not superior to guideline-recommended aspirin/dipyridamole or clopidogrel alone to prevent recurrent stroke in patients with recent stroke or TIA in the TARDIS trial.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news